NYSEHealth CareHealth Care TechnologyS&P MidCap 400
$32.51
-0.67 (-2.02%)
Close of Nov 06, 2026 · end-of-day data
DOCS 8-K filings in 2023
Every material Form 8-K Doximity filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Doximity reported fiscal second-quarter 2024 results for the period ended September 30, 2023, with revenue up 11% and net income up from the prior-year quarter. The company updated its fiscal 2024 revenue and adjusted EBITDA guidance and authorized a new $70 million share repurchase program, while operating cash flow fell 67% year-over-year.
Revenue of $113.6 million, up 11% from $102.2 million; net income of $30.6 million versus $26.3 million
Diluted net income per share of $0.15 versus $0.12; adjusted EBITDA of $54.2 million, up 18%
Operating cash flow of $12.9 million, down 67% from $39.5 million; restructuring expense of $7.9 million included in net income
Fiscal 2024 revenue guidance updated to $460 million to $472 million; board authorized up to $70 million in buybacks over the next 12 months
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Doximity filing is on SEC EDGAR ↗. 8-K briefs of other companies →